Experimental Triple-Drug cocktail targets Hard-to-Treat leukemia

This early-phase trial tests whether adding regorafenib to the standard venetoclax and azacitidine regimen is safe and effective for people with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. About 20 adults will receive the three-drug combination to find the best dose and check for side effects. The goal is to control the disease, not cure it, as ongoing management is typically needed.